▁British 10.375
▁Bi 10.859375
ote 5.58203125
ch 4.43359375
' 7.37109375
s 1.0361328125
▁Mar 9.0078125
im 8.0
ast 9.1796875
at 6.12890625
▁anti 10.0625
- 0.798828125
can 5.90625
cer 0.181884765625
▁treatment 5.1328125
▁to 5.21484375
▁be 4.01953125
▁review 7.59765625
ed 0.0626220703125
▁at 3.802734375
▁ES 12.1171875
MO 3.595703125
▁conference 5.3046875
▁in 3.3984375
▁Vienna 4.859375
▁ 3.685546875
<0x0A> 12.140625
<0x0A> 3.869140625
B 4.671875
rit 3.716796875
ish 0.4619140625
▁Bi 7.078125
ote 0.1221923828125
ch 0.1619873046875
, 3.150390625
▁a 3.041015625
▁leading 4.40625
▁UK 2.1875
▁bi 1.3466796875
ote 0.0428466796875
chn 0.634765625
ology 0.012847900390625
▁company 1.279296875
, 0.66015625
▁announced 3.525390625
▁today 4.06640625
▁that 0.481689453125
▁updated 12.6015625
▁results 2.4453125
▁from 0.329833984375
▁its 1.2666015625
▁Ph 0.962890625
ase 0.0022373199462890625
▁III 3.068359375
▁clin 1.376953125
ical 0.00153350830078125
▁trial 0.41845703125
▁of 0.70263671875
▁Mar 7.41796875
im 3.73828125
ast 0.324462890625
at 0.0005536079406738281
, 1.712890625
▁an 1.361328125
▁investig 0.5595703125
ational 0.0092926025390625
▁anti 2.5625
- 0.0208740234375
can 0.0919189453125
cer 0.0002065896987915039
▁drug 1.9326171875
, 0.5400390625
▁will 2.5078125
▁be 0.0234222412109375
▁presented 0.13916015625
▁at 0.45458984375
▁the 0.4267578125
▁European 1.6396484375
▁Society 0.01702880859375
▁for 0.33935546875
▁Medical 0.0093841552734375
▁On 0.032501220703125
col 0.00016379356384277344
ogy 2.5153160095214844e-05
▁( 0.55615234375
ES 0.005168914794921875
MO 0.00025773048400878906
) 0.038909912109375
▁annual 2.751953125
▁conference 1.1396484375
▁in 0.465576171875
▁Vienna 0.1666259765625
▁next 4.6015625
▁month 1.7060546875
. 0.11944580078125
▁Mar 3.234375
im 0.002681732177734375
ast 0.0015230178833007812
at 0.0004048347473144531
▁is 0.568359375
▁an 1.822265625
▁or 1.775390625
ally 1.2705078125
- 1.6064453125
active 2.033203125
▁matrix 9.53125
▁metal 0.09112548828125
lo 0.0021724700927734375
prote 0.029022216796875
in 0.1007080078125
ase 0.006023406982421875
▁( 0.9912109375
M 0.037078857421875
MP 0.0036716461181640625
) 0.369873046875
▁in 0.038482666015625
hib 2.562999725341797e-05
itor 0.0025959014892578125
▁that 1.4052734375
▁British 14.578125
▁Bi 0.004150390625
ote 9.047985076904297e-05
ch 0.01039886474609375
▁is 1.2314453125
▁developing 0.1688232421875
▁for 0.8388671875
▁the 0.2900390625
▁treatment 0.1597900390625
▁of 0.0107879638671875
▁g 3.453125
astro 0.5458984375
int 0.10028076171875
est 0.0012369155883789062
inal 0.00014829635620117188
▁can 1.3974609375
cers 3.981590270996094e-05
, 1.5771484375
▁including 0.76171875
▁pan 1.845703125
cre 0.002986907958984375
atic 0.00632476806640625
, 1.68359375
▁g 2.677734375
astr 0.0517578125
ic 0.0009756088256835938
, 0.59423828125
▁and 1.4951171875
▁col 0.95361328125
ore 0.001239776611328125
ct 7.128715515136719e-05
al 0.0001493692398071289
▁can 0.53662109375
cers 0.00020396709442138672
. 0.1856689453125
<0x0A> 0.8408203125
<0x0A> 0.0906982421875
The 1.94921875
▁new 4.15234375
▁data 1.1142578125
▁will 1.5625
▁provide 3.6796875
▁an 2.404296875
▁analysis 5.046875
▁of 0.076416015625
▁overall 3.28125
▁surv 0.15185546875
ival 0.0010204315185546875
▁from 3.107421875
▁the 0.513671875
▁double 4.8515625
- 0.1181640625
bl 0.0077362060546875
ind 0.00011336803436279297
, 0.58203125
▁place 0.732421875
bo 0.0001825094223022461
- 0.050567626953125
control 0.0027256011962890625
led 0.0014276504516601562
▁trial 2.076171875
▁evalu 4.13671875
ating 0.0003790855407714844
▁Mar 0.693359375
im 0.0005030632019042969
ast 0.0013742446899414062
at 0.0009794235229492188
▁in 0.8134765625
▁combination 1.091796875
▁with 0.00997161865234375
▁gem 1.9931640625
cit 0.0010814666748046875
ab 0.0001882314682006836
ine 0.00034618377685546875
, 2.5625
▁a 1.2822265625
▁standard 1.708984375
▁chem 2.015625
other 0.04193115234375
apy 0.1405029296875
, 2.869140625
▁in 0.474609375
▁patients 0.55712890625
▁with 0.044219970703125
▁advanced 1.0068359375
▁pan 0.365234375
cre 0.0003998279571533203
atic 0.00524139404296875
▁cancer 0.3857421875
. 0.62548828125
▁Pre 4.04296875
vious 3.068359375
▁results 1.37109375
▁from 0.79296875
▁the 0.383544921875
▁trial 0.8671875
▁showed 1.21484375
▁the 3.884765625
▁combination 2.287109375
▁significantly 3.08984375
▁improved 1.4208984375
▁pro 2.400390625
gression 0.00225067138671875
- 0.055908203125
free 0.0017852783203125
▁surv 0.04937744140625
ival 0.00011599063873291016
▁compared 1.7177734375
▁to 0.51220703125
▁gem 1.01953125
cit 0.0008554458618164062
ab 0.00021159648895263672
ine 0.00019276142120361328
▁alone 0.1839599609375
. 0.6630859375
▁The 1.7578125
▁trial 3.486328125
▁en 3.67578125
rolled 0.00948333740234375
▁over 3.84375
▁ 0.01015472412109375
9 3.451171875
0 0.14501953125
0 0.1036376953125
▁patients 0.061187744140625
▁across 2.76953125
▁ 0.50927734375
1 1.171875
5 2.26171875
0 2.169921875
▁cent 1.19921875
ers 0.80908203125
▁in 0.2099609375
▁Europe 1.681640625
, 0.4462890625
▁Australia 2.5234375
, 0.426513671875
▁Canada 2.21484375
▁and 1.384765625
▁the 0.5205078125
▁United 0.66455078125
▁States 0.024505615234375
. 0.26953125
<0x0A> 0.53173828125
<0x0A> 0.0211029052734375
“ 25.0625
We 11.3359375
▁are 0.50244140625
▁very 1.7109375
▁pleased 0.41455078125
▁to 0.7744140625
▁have 1.8271484375
▁the 2.4140625
▁opportunity 0.53564453125
▁to 0.0216827392578125
▁present 0.487060546875
▁these 1.330078125
▁important 4.06640625
▁new 1.8916015625
▁data 0.89892578125
▁on 2.486328125
▁overall 5.00390625
▁surv 0.002796173095703125
ival 0.0005435943603515625
▁with 3.501953125
▁Mar 0.6298828125
im 0.00022602081298828125
ast 0.0020732879638671875
at 0.0003771781921386719
▁at 1.650390625
▁the 1.2802734375
▁ES 0.18212890625
MO 0.0008058547973632812
▁conference 0.876953125
,” 24.96875
▁said 7.27734375
▁Dr 1.642578125
. 0.58837890625
▁Peter 3.81640625
▁Parker 7.58984375
, 0.08258056640625
▁Chief 1.2392578125
▁Medical 1.4404296875
▁Officer 0.040985107421875
▁at 1.1875
▁British 0.0309600830078125
▁Bi 0.00241851806640625
ote 2.5033950805664062e-05
ch 0.005199432373046875
. 0.264404296875
▁“ 24.640625
Pan 7.14453125
cre 0.0149383544921875
atic 0.01079559326171875
▁cancer 0.1287841796875
▁remains 2.205078125
▁an 2.48828125
▁area 3.69140625
▁of 0.11358642578125
▁high 1.6416015625
▁un 0.03521728515625
met 0.0011568069458007812
▁medical 0.70361328125
▁need 0.011810302734375
, 0.99267578125
▁and 0.802734375
▁we 1.541015625
▁believe 1.1787109375
▁Mar 1.244140625
im 0.00027680397033691406
ast 0.0018138885498046875
at 0.005664825439453125
▁has 0.78369140625
▁the 0.1875
▁potential 0.0200653076171875
▁to 0.01690673828125
▁become 2.087890625
▁an 1.2314453125
▁important 0.137939453125
▁new 0.888671875
▁treatment 0.466064453125
▁option 0.2255859375
▁for 0.301513671875
▁patients 0.55029296875
▁with 0.59521484375
▁this 0.9580078125
▁dev 1.7705078125
ast 0.0003170967102050781
ating 0.0003027915954589844
▁disease 0.159423828125
.” 24.125
<0x0A> 0.703125
<0x0A> 0.054412841796875
B 2.3671875
rit 0.017425537109375
ish 0.001865386962890625
▁Bi 0.003467559814453125
ote 9.28640365600586e-05
ch 0.004772186279296875
▁also 4.01953125
▁plans 2.685546875
▁to 0.0230712890625
▁meet 7.12109375
▁with 0.08233642578125
▁the 2.3125
▁European 1.5634765625
▁Medic 1.25
ines 0.0015964508056640625
▁Agency 0.01580810546875
▁( 0.51611328125
EMA 0.0125274658203125
) 0.06695556640625
▁and 2.26953125
▁U 4.6953125
. 0.000965118408203125
S 0.07208251953125
. 0.024658203125
▁Food 0.04205322265625
▁and 0.0823974609375
▁D 0.001903533935546875
rug 9.369850158691406e-05
▁Administration 0.01470184326171875
▁( 0.053466796875
F 0.00684356689453125
DA 0.0005903244018554688
) 0.03759765625
▁in 1.6923828125
▁the 0.72265625
▁coming 0.60888671875
▁months 0.7099609375
▁to 0.56396484375
▁discuss 0.380126953125
▁fil 4.9375
ing 0.02032470703125
▁for 1.55859375
▁market 1.98046875
ing 0.09130859375
▁appro 1.2626953125
val 7.104873657226562e-05
▁of 0.9873046875
▁Mar 0.1339111328125
im 0.0003254413604736328
ast 0.0016222000122070312
at 0.0012273788452148438
▁based 7.58203125
▁on 0.0478515625
▁the 0.75830078125
▁final 6.38671875
▁data 1.814453125
▁from 0.416748046875
▁this 1.6748046875
▁trial 1.1767578125
. 0.2099609375
▁Mar 3.4375
im 0.0011625289916992188
ast 0.0016012191772460938
at 0.0013399124145507812
▁has 2.00390625
▁been 1.0615234375
▁granted 0.7568359375
▁Or 0.83447265625
phan 0.0004973411560058594
▁D 0.1331787109375
rug 0.0025005340576171875
▁status 2.197265625
▁for 2.490234375
▁pan 1.6923828125
cre 0.0004105567932128906
atic 0.006565093994140625
▁cancer 0.06268310546875
▁in 0.94384765625
▁both 2.62109375
▁the 0.2425537109375
▁EU 2.30078125
▁and 0.0209808349609375
▁U 1.5625
. 0.0004930496215820312
S 0.00545501708984375
. 0.357177734375
▁British 2.892578125
▁Bi 0.0016927719116210938
ote 2.7179718017578125e-05
ch 0.0041046142578125
▁previously 5.640625
▁reported 2.71484375
▁the 2.755859375
▁trial 4.6953125
▁met 2.06640625
▁its 0.45947265625
▁primary 0.07489013671875
▁endpoint 0.40185546875
▁of 0.9990234375
▁pro 2.353515625
gression 0.0009660720825195312
- 0.090087890625
free 0.004680633544921875
▁surv 0.0094146728515625
ival 0.00024509429931640625
, 2.412109375
▁but 4.5078125
▁the 2.271484375
▁data 2.32421875
▁on 4.02734375
▁overall 0.060760498046875
▁surv 0.00258636474609375
ival 7.224082946777344e-05
▁was 1.96875
▁not 0.5595703125
▁yet 1.41796875
▁m 5.15625
ature 0.0264739990234375
▁at 1.5439453125
▁the 0.2086181640625
▁time 0.0535888671875
▁of 0.3369140625
▁that 3.263671875
▁analysis 3.71875
. 0.11993408203125
<0x0A> 0.62353515625
<0x0A> 0.0228118896484375
The 2.810546875
▁ES 3.908203125
MO 0.00231170654296875
▁annual 1.9267578125
▁conference 0.370849609375
▁is 1.6337890625
▁the 1.2373046875
▁pre 5.75390625
em 0.88330078125
inent 0.0005106925964355469
▁European 3.234375
▁event 3.27734375
▁in 1.556640625
▁on 1.86328125
col 0.01380157470703125
ogy 3.826618194580078e-05
, 0.99560546875
▁bringing 1.9736328125
▁together 0.046356201171875
▁leading 2.26953125
▁on 2.712890625
col 0.39599609375
ogy 6.520748138427734e-05
▁profession 2.1171875
als 3.707408905029297e-05
▁and 2.154296875
▁research 1.75390625
ers 0.037078857421875
▁from 0.6357421875
▁around 0.7744140625
▁the 0.0033016204833984375
▁world 0.140625
▁to 1.1953125
▁present 2.240234375
▁and 1.5966796875
▁discuss 0.09259033203125
▁the 0.302734375
▁latest 0.216796875
▁research 1.6982421875
▁find 2.982421875
ings 1.2278556823730469e-05
▁in 1.0654296875
▁clin 3.462890625
ical 0.0024890899658203125
▁on 1.0498046875
col 0.000507354736328125
ogy 1.9788742065429688e-05
. 0.341552734375
▁The 1.9189453125
▁conference 0.6875
▁will 0.97705078125
▁be 0.85888671875
▁held 0.0517578125
▁from 1.3984375
▁September 1.6630859375
▁ 0.0052642822265625
2 0.93994140625
7 2.248046875
▁to 1.1904296875
▁October 0.375244140625
▁ 0.001873016357421875
1 0.658203125
▁in 1.79296875
▁Vienna 0.01387786865234375
, 0.256103515625
▁Austria 0.0287933349609375
. 0.2071533203125
